✦ LIBER ✦

Results of the GAP 160701 study: A phase 3 clinical trial of intravenous immunoglobulin for mild-to-moderate Alzheimer's disease

✍ Scribed by Relkin, Norman

Book ID: 122019959
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 54 KB
Volume: 9
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.04.270

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 3 Trials of Solanezumab for Mild-t

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

✍ Doody, Rachelle S.; Thomas, Ronald G.; Farlow, Martin; Iwatsubo, Takeshi; Vellas 📂 Article 📅 2014 🏛 Massachusetts Medical Society 🌐 English ⚖ 514 KB

Intravenous immunoglobulin for treatment

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

✍ Dodel, Richard; Rominger, Axel; Bartenstein, Peter; Barkhof, Frederik; Blennow, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 746 KB

Efficacy and Safety of Intravenous Solan

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies

✍ Hake, Ann M.; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 50 KB

Combined treatment with cerebrolysin and

Combined treatment with cerebrolysin and donepezil in mild to moderate alzheimer's disease: Results of a double-blind, randomized clinical trial

✍ Anton Alvarez; Ramon Cacabelos; Manuel Aleixandre; Carlos Linares; Elias Granizo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 169 KB

S3-02-03: Results of a one-year randomiz

S3-02-03: Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer’s disease

✍ Rachelle S. Doody; Svetlana Gavrilova; Mary Sano; Ronald Thomas; Paul Aisen; Ser 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A comparison of hippocampal atrophy algo

A comparison of hippocampal atrophy algorithms to select outcome measures for clinical trials in mild-to-moderate Alzheimer's disease

✍ Burns, Leah; Rueckert, Daniel; Bhagwagar, Zubin; Donohue, Michael; Wolz, Robin; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB